Get to know our clinical trials
Clinical trial to compare pralsetinib with standard treatment of RET-mutated medullary thyroid cancer
THIS RESEARCH STUDY (CLINICAL TRIAL) WILL EVALUATE THE SAFETY AND EFFECTS, POSITIVE OR NEGATIVE, OF PRALSETINIB COMPARED TO THE REFERENCE TREATMENT CHOSEN BY THE STUDY DOCTOR WITH VANDETANIB OR CABOZANTINIB TO DETERMINE IF IT IS AN EFFECTIVE WAY TO TREAT TNBC. PRALSETINIB WAS DESIGNED TO TREAT PATIENTS WITH CANCERS THAT HAVE ALTERATIONS IN THE RET GENE THAT CAN CAUSE THE TUMOR TO GROW. VARIATIONS IN RET (CALLED RET MUTATIONS) ARE FREQUENTLY DETECTED IN TNBC. PRELIMINARY DATA FROM CLINICAL STUDIES WITH PRALSETINIB HAVE SHOWN THAT THE DRUG IS EFFECTIVE IN PATIENTS WITH TNBC WITH AN ACCEPTABLE SAFETY PROFILE. THIS RESEARCH STUDY IS AN INTERNATIONAL, OPEN-LABEL, RANDOMIZED STUDY DESIGNED TO COMPARE THE EFFECTS OF AN INVESTIGATIONAL NEW DRUG CALLED PRALSETINIB ("STUDY DRUG") WITH THE EFFECT OF REFERENCE THERAPEUTIC OPTIONS FOR RET-MUTATED TNBC.
- RANDOMIZED, OPEN-LABEL PHASE III STUDY TO COMPARE PRALSETINIB WITH STANDARD TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER
- Code EudraCT: 2020-005269-15
- Protocol number: CO42865
- Promoter: F. Hoffmann-La Roche Ltd.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.